Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Corbus completes Phase 1b trial visits, but key obesity data won’t arrive until late 2026.

Risk flags

• ●There is a significant execution risk due to the long timeline before topline data—September 2026—meaning investors will have no meaningful clinical readout for nearly two years. Delays or protocol deviations could further extend this period, increasing uncertainty.
• ●The efficacy evidence is limited to a small Phase 1a cohort (n=9 treated, n=3 placebo) with a 2.9% placebo-adjusted weight loss by Day 14, which is insufficient to draw conclusions about long-term or clinically meaningful benefit. Larger, longer-term data is needed to validate the drug’s potential.
• ●No financial data or operational KPIs are disclosed, preventing assessment of the company’s cash runway, burn rate, or ability to fund operations through the next major milestone. This lack of transparency increases financial risk for investors.
• ●The promotional language around CRB-913’s differentiation from GLP-1 and other therapies is not yet substantiated by comparative clinical data, raising the risk that expectations are being set without adequate supporting evidence.

Bottom line

This announcement signals that Corbus has reached a planned clinical milestone, but offers no new efficacy or safety data and no financial disclosures. The company’s narrative leans on the promise of CRB-913 as a differentiated obesity therapy, yet the only efficacy evidence is from a very small, short-term Phase 1a cohort. Investors face a long wait—at least until September 2026—for topline Phase 1b results, with no interim readouts or financial updates provided. The absence of financial data means there is no visibility into the company’s ability to sustain operations through this period. The most important takeaway is that this is a procedural update, not a value inflection point, and the risk profile remains high until substantive clinical or financial data is released.

Announcement summary

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings, Inc. announced the last patient has completed their last clinical visit in the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States. The trial includes three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily as well as a placebo cohort, with randomization of 1:1:1:1. Participants were dosed for 12-weeks followed by a four-week safety follow-up. In the Phase 1a study, the SAD portion enrolled 64 participants across 8 cohorts and the MAD portion enrolled 48 participants across 4 cohorts, including a dedicated obese cohort. The highest SAD dose tested was 600 mg/day, and the highest MAD dose tested was 150 mg/day. The company projects topline data readout for the CANYON-1 study in September 2026.

Disagree with this article?